Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be of reproductive age from 18 to 45 years~* Must be choosing LNG-IUC for contraception~* Must be English-speaking~* Be willing to avoid additional use of exogenous hormones, such as oral contraceptives, for the duration of the study~* Be willing to avoid additional use of nonsteroidal antiinflammatory drugs, such as ibuprofen or aspirin for the duration of the study~* Be willing to comply with the study protocol, keep the bleeding diary and comply with follow-up visits and telephone interviews as scheduled~* Be willing and able to provide informed consent~Exclusion Criteria:~* Known or suspected pregnancy~* Contraindication to estrogen use, such as presence or history of:~  * venous thromboembolism~ * Arterial thrombosis~ * Thrombophilia disorders, or known family history of~ * Hypertension~ * Migraine headaches with aura or focal neurologic involvement, or any migraine over age 35 years~* Recent or planned future major surgery which will result in prolonged immobilization during the study period~* Presence or history of severe hepatic disease or liver tumors~* Known or suspected estrogen-dependent neoplasm~* Vaginal bleeding of unknown etiology~* Any cigarette smoking and age over 35 years~* Contraindications to nonsteroidal anti-inflammatory use, such as presence or history of:~  * Gastrointestinal ulcer disease~ * Renal insufficiency or failure~ * Aspirin-induced asthma or hypersensitivity reaction~ * Systemic lupus erythematosus (SLE) and mixed connective tissue disorders~ * Use of anticoagulants~ * Cardiovascular disease~* Use of medications that alter estrogen metabolism, i.e. rifampin, certain anti-seizure medications~* Regular use of an NSAID~* Current diagnosis of menorrhagia, metrorrhagia, symptomatic uterine fibroids, or endometrial polyp~* Hypersensitivity or allergy to any of the components of the estradiol patch~* Use of injectable contraception within 6 months of the start of the study medication~* Delivery or abortion in the previous 4 weeks~* Prior use of LNG-IUD~* Any condition, that in the opinion of the investigator, would contraindicate study participation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- transdermal estradiol (Type: EXPERIMENTAL): participants will be randomized to transdermal estradiol
- oral naproxen (Type: EXPERIMENTAL): participants will be randomized to oral naproxen
- oral placebo (Type: PLACEBO_COMPARATOR): participants will be randomized to oral placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).